Back to search

Article

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective Review

2025-11-28

Abstract excerpt

<title>Abstract</title> <p>Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy can disrupt the course of oncology treatment. Data guiding the safety and effectiveness of biologic agents for cirAEs remain limited. We therefore aimed evaluate the efficacy and oncologic safety of biologic therapy for ICI-associated cirAEs. We conducted a retrospective chart review of adult...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5911f3e5-2748-56a3-98a3-8792d973e6b7
DOI
10.21203/rs.3.rs-8065496/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewDOI 10.21203/rs.3.rs-8065496/v1
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity
Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity
A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSemantic proximity
The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity
Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.Semantic proximity
Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity
Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity
Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelSemantic proximity
Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Semantic proximity
Select a neighboring publication to make it the new centre.